FIMECS Announces to be Awarded the First Prize at the KPMG Global Tech Innovator Competition in Japan 2022 and Invited for World Championship Held in Lisbon, Portugal in November
News release Download PDF
Kanagawa, Japan, 5th, August 2022 – FIMECS, Inc. (CEO: Yusuke Tominari, Ph.D., “FIMECS”) a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Kanae Gamo, Ph.D. Co-founder, CSO of FIMECS made a pitch at the KPMG Global Tech Innovator Competition in Japan 2022 (27 July 2022, CIC Tokyo) and FIMECS was awarded the first prize. (See official announcement)
The event was held as Japan semi-final of KPMG Private Enterprise’s Global Tech Innovator 2022 (“World Final”) in Lisbon, Portugal in November 2022 organized by KPMG International Limited（“KPMG”）. Seventeen start-ups focusing on emerging technologies such as AI, Life science, Healthcare, and Fintech had a pitch, which is evaluated by judges including experts other than KPMG. FIMECS was awarded the first prize and invited for the World Final which the finalists from twenty-four countries will pitch their innovations. In addition, a large number of founders and investors will participate as audiences and the finalists have an opportunity to get higher reputation in the world including Europe.
“We are very excited to be awarded the first prize of KPMG Global Tech Innovator Competition in Japan 2022 organized by worldwide top tier audit firm, KPMG.” said Yusuke Tominari, Ph.D., Co-founder, CEO of FIMECS. “We believe that our growth strategy based on targeted protein degradation discovery platform, RaPPIDS™ has been highly praised. We will promote our research to discover the innovative medicines as well as prepare the pitch for the World Final.”
Kanae Gamo, Ph.D. will be a presenter at the World Final as well as Japan semi-final.
About FIMECS, Inc.
FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDS™ platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects. https://www.fimecs.com/eng/
RaPPIDS™ (Rapid Protein Proteolysis Inducer Discovery System) is one of the proprietary drug discovery platforms of FIMECS, Inc. used to generate therapeutic candidates of the targeted protein degrader. The platform allows synthesizing and evaluating various degraders quickly based on the company’s proprietary know-how and diversity-oriented synthesis, and delivery of the drug candidates with the best combination of target protein binders, linkers, and E3 ligase binders. Moreover, RaPPIDS™ platform enables the discovery of novel E3 ligase binders, which is expected to dramatically expand the range of target proteins that can be degraded.
# # #
FIMECS, Inc. Media Contact:
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa